CZ297342B6 - Lécivo pro lécení maniodepresivních bipolárních poruch u savcu - Google Patents

Lécivo pro lécení maniodepresivních bipolárních poruch u savcu

Info

Publication number
CZ297342B6
CZ297342B6 CZ0427798A CZ427798A CZ297342B6 CZ 297342 B6 CZ297342 B6 CZ 297342B6 CZ 0427798 A CZ0427798 A CZ 0427798A CZ 427798 A CZ427798 A CZ 427798A CZ 297342 B6 CZ297342 B6 CZ 297342B6
Authority
CZ
Czechia
Prior art keywords
mammals
carbon atoms
general formula
bipolar disorders
medicament
Prior art date
Application number
CZ0427798A
Other languages
English (en)
Other versions
CZ427798A3 (cs
Inventor
P. Shank@Richard
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/009178 external-priority patent/WO1997047135A1/en
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of CZ427798A3 publication Critical patent/CZ427798A3/cs
Publication of CZ297342B6 publication Critical patent/CZ297342B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
    • H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
    • H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
    • H04N21/442—Monitoring of processes or resources, e.g. detecting the failure of a recording device, monitoring the downstream bandwidth, the number of times a movie has been viewed, the storage space available from the internal hard disk
    • H04N21/44213—Monitoring of end-user related data
    • H04N21/44222—Analytics of user selections, e.g. selection of programs or purchase activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Social Psychology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Multimedia (AREA)
  • Signal Processing (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Pouzití sulfamátových sloucenin obecného vzorce I, kde X predstavuje skupinu CH.sub.2.n. nebo atom kyslíku; R.sub.1.n. predstavuje atom vodíku nebo alkylskupinu s 1 az 4 atomy uhlíku; a R.sub.2.n., R.sub.3.n., R.sub.4.n., R.sub.5.n. predstavuje nezávisle vzdy atom vodíku nebo nizsí alkylskupinu s 1az 3 atomy uhlíku a kdyz X je atom kyslíku, R.sub.2.n. a R.sub.3.n. a/nebo R.sub.4.n. a R.sub.5.n. mohou spolecne predstavovat methylendioxyskupinu obecného vzorce II, kde R.sub.6.n. a R.sub.7.n. jsou stejné nebo odlisné a kazdý predstavuje atom vodíku nebo nizsí alkylskupinu s 1 az 3 atomy uhlíku nebo R.sub.6.n. a R.sub.7.n. predstavují alkylskupiny, které jsou spolu spojeny za vzniku cyklopentylového nebo cyklohexylového kruhu; zejména topiramatu, pro výrobu léciva pro lécení maniodepresivních bipolárních poruch u savcu.
CZ0427798A 1996-06-28 1997-06-24 Lécivo pro lécení maniodepresivních bipolárních poruch u savcu CZ297342B6 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2085096P 1996-06-28 1996-06-28
PCT/US1997/009178 WO1997047135A1 (en) 1996-06-06 1997-06-04 Method and apparatus for automatically determining and dynamically updating user preferences in an entertainment system
US08/881,008 US5753693A (en) 1996-06-28 1997-06-23 Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder

Publications (2)

Publication Number Publication Date
CZ427798A3 CZ427798A3 (cs) 1999-08-11
CZ297342B6 true CZ297342B6 (cs) 2006-11-15

Family

ID=26693960

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ0427798A CZ297342B6 (cs) 1996-06-28 1997-06-24 Lécivo pro lécení maniodepresivních bipolárních poruch u savcu

Country Status (21)

Country Link
US (1) US5753693A (cs)
EP (1) EP0932398B1 (cs)
JP (1) JP2002515875A (cs)
KR (1) KR20000022233A (cs)
CN (1) CN1224350A (cs)
AP (1) AP1401A (cs)
AT (1) ATE330593T1 (cs)
AU (1) AU739363B2 (cs)
BR (1) BR9712783A (cs)
CA (1) CA2258895C (cs)
CZ (1) CZ297342B6 (cs)
DE (1) DE69736183T2 (cs)
ES (1) ES2267144T3 (cs)
HU (1) HUP0003381A3 (cs)
IL (1) IL127714A (cs)
NO (1) NO317641B1 (cs)
NZ (1) NZ333565A (cs)
RU (1) RU2185824C2 (cs)
SK (1) SK180498A3 (cs)
WO (1) WO1998000123A1 (cs)
ZA (1) ZA975773B (cs)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1143917T3 (da) 1998-11-17 2004-06-01 Ortho Mcneil Pharm Inc Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
HUP0101299A3 (en) * 1998-12-03 2002-04-29 Ortho Mcneil Pharm Inc Use of topiramate and derivatives for manufacturing medicament useful for treating schizophrenia
US6552000B2 (en) 1999-02-08 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating autism
NZ513643A (en) * 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
MXPA01010217A (es) * 1999-04-08 2005-09-08 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos.
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
CA2686633A1 (en) 1999-06-14 2000-12-21 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP1309325A1 (en) * 2000-08-02 2003-05-14 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
EP1423127A1 (en) * 2001-08-30 2004-06-02 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US20040235957A1 (en) * 2001-10-12 2004-11-25 David Bleakman Use of sulfonamide derivatives as pharmaceuticals compounds
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN100360117C (zh) * 2002-06-21 2008-01-09 转化医药公司 具有提高的溶出度的药物组合物
NZ537543A (en) * 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US7196209B2 (en) * 2002-10-31 2007-03-27 Ortho-Mcneil Pharmaceutical, Inc. Continuous process for the preparation of fructopyranose sulfamate derivatives
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
AU2004312084A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
BRPI0514278A (pt) * 2004-08-24 2008-06-10 Janssen Pharmaceutica Nv derivados de sulfamida de heteroarila benzo-fundida úteis como agentes anti-convulsivante
WO2006127184A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
WO2007137167A2 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
US20080131501A1 (en) 2006-12-04 2008-06-05 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2050852C1 (ru) * 1992-06-05 1995-12-27 Замощина Татьяна Алексеевна Способ пролонгирования биологической активности солей лития
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLEVELAND CLINIC JOURNAL OF MEDICINE, VOL56, NO8, 1989, 756-761 *
EPILEPSY RESEARCH, VOL 24, NO 2, 1996, 73-77 *
La ENCaPHALE, VOL21, SPEC ISSUE NO 6, 1995, 21-32 *
PSYCHOPHARMACOLOGY, VOL 29, NO 4, 1993, 447-456 *

Also Published As

Publication number Publication date
KR20000022233A (ko) 2000-04-25
IL127714A0 (en) 1999-10-28
AP1401A (en) 2005-04-29
AU739363B2 (en) 2001-10-11
SK180498A3 (en) 2000-03-13
CZ427798A3 (cs) 1999-08-11
BR9712783A (pt) 2000-10-24
NZ333565A (en) 2000-07-28
IL127714A (en) 2004-08-31
US5753693A (en) 1998-05-19
DE69736183T2 (de) 2007-04-26
JP2002515875A (ja) 2002-05-28
NO986051D0 (no) 1998-12-22
EP0932398A1 (en) 1999-08-04
CN1224350A (zh) 1999-07-28
AU3409697A (en) 1998-01-21
EP0932398B1 (en) 2006-06-21
DE69736183D1 (de) 2006-08-03
CA2258895A1 (en) 1998-01-08
HUP0003381A2 (hu) 2001-05-28
AP9801427A0 (en) 1998-12-31
ZA975773B (en) 1998-12-28
HUP0003381A3 (en) 2001-12-28
ES2267144T3 (es) 2007-03-01
NO986051L (no) 1999-02-23
CA2258895C (en) 2006-06-06
ATE330593T1 (de) 2006-07-15
WO1998000123A1 (en) 1998-01-08
RU2185824C2 (ru) 2002-07-27
NO317641B1 (no) 2004-11-29

Similar Documents

Publication Publication Date Title
CZ297342B6 (cs) Lécivo pro lécení maniodepresivních bipolárních poruch u savcu
FI934626A0 (fi) Substituerade bensylaminokinuklidiner
ATE139783T1 (de) Azasteroide zur behandlung prostatischer hypertrophie, ihre herstellung und verwendung
CA2212326A1 (en) O-carbamoyl-(d)-phenylalanilol compounds and process for preparing the same
AU3091084A (en) 1,8-naphthyridine derivatives
WO2000042996A3 (en) Use of anticonvulsant derivatives for treating cluster headaches
ES557199A0 (es) Un procedimiento para la preparacion de nuevos derivados de ciclopenta(d)pirimidina
NZ334848A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases caused by fungi and bacteria
SE8505887D0 (sv) Indoler
BR9712503A (pt) Derivados anticonvulsivos úteis no tratamento de dor neuropática
EP0567090A3 (cs)
EP1122252A4 (en) CONDENSED HEREROCYCLIC NITROGEN COMPOUNDS; MANUFACTURING PROCESS AND AGENTS CONTAINING THEM
ZA879663B (en) Propiophenone derivatives for treatmento of pollakiuria(frequency urination)
ATE52499T1 (de) 5-alkylsulfonylsalicylanilide und mikrobizide zusammensetzungen fuer die regulierung des wachstums von mikroorganismen.
ES2045282T3 (es) Un procedimiento para la preparacion de antraciclinona 4-sustituida.
NZ219052A (en) Octahydroindolizine derivatives and pharmaceutical compositions
BE903438A (fr) Nouveaux derives de la phenethylaminoalcoyle-6 furo-(3,4-c)-pyridine, leur preparation et compositions therapeutiques a base de ceux-ci
NZ333587A (en) Topiramate derivatives useful in treating psoriasis
ATE64921T1 (de) Benzochinonderivate, ihre herstellung und verwendung.
MY101895A (en) 5-hetero-or aryl-substituted-imidazo [2,1-a] isoquinolines
GB1205740A (en) Process for the isomerization of aromatic alkenyl compounds
FR2543947B1 (fr) Nouveaux tetra-alkyl-2,2,5,5 cyclohexanone-4 01-1 et leurs derives sulfonyles, leur preparation et leur application a la synthese de lactones cyclopropaniques
EP0760375A4 (en) Antitumor indolopyprolocarbazole derivative
AU5521086A (en) Novel diamine derivatives
ATE63537T1 (de) Carbacyclin-derivate.

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20070624